Q3 2026 earnings snapshot and how the story stacks up

Clorox (CLX) has just posted Q3 2026 results with revenue of US$1,670 million and basic EPS of US$1.54, setting the tone for how investors read its latest trading update. Over the past few quarters the company has seen revenue move in a tight band around US$1,670 million while basic EPS has ranged from US$0.65 in Q1 2026 to US$2.70 in Q4 2025, giving you a clear view of how earnings swing through the year. With trailing twelve month earnings growth of 8.9% and a higher net margin than a year ago, the release points to a business where profitability metrics remain central to the story.

See our full analysis for Clorox.

With the headline numbers on the table, the next step is to see how these results line up with the prevailing narratives around Clorox and where the data starts to challenge those views.

Earnings up 8.9% with wider 11.2% margin

• On a trailing 12 month view, Clorox generated US$756 million of net income on US$6.8b of revenue, which works out to 8.9% earnings growth and an 11.2% net margin compared with 9.9% a year ago.
• Consensus narrative sees ERP and digital upgrades helping margins over time, and the current 11.2% trailing margin versus 9.9% last year gives some evidence of that, although:
  • Earnings growth of 8.9% over the past year and 7.4% per year over five years is solid but not explosive, so the claim of sustained margin expansion is still being tested by each new quarter.
  • Forecast earnings growth of roughly 8.05% a year is only slightly above the recent 7.4% five year pace, which suggests analysts are not yet baking in a big step change in profitability despite the ERP story.

Valuation gap vs DCF fair value

• With a P/E of 13.9x and a share price of US$87.11, the stock screens below an analyst price target of US$108.24 and well below the quoted DCF fair value of about US$171.94.
• Bulls argue that ERP driven efficiencies and product platforms can lift earnings enough to justify higher multiples, and today’s numbers partly line up with that idea, but also raise questions:
  • The 13.9x P/E is lower than both the 25x peer average and 18.1x industry figure, so anyone backing the bullish case is effectively betting that current earnings quality and 11.2% net margin are not fully reflected in the price.
  • At the same time, the trailing 12 month revenue of US$6.8b is slightly below the earlier US$7.1b reading in the data, so the valuation gap rests more on margin resilience and earnings stability than on clear top line acceleration right now.

On these numbers, short term steadiness in revenue and margins gives bulls some footing, but the valuation gap to US$171.94 assumes the more optimistic earnings path really comes through over time. 🐂 Clorox Bull Case

Cash flow coverage keeps bears cautious

• The trailing dividend yield of 5.69% is flagged as not well covered by free cash flow, and debt is also described as not well covered by operating cash flow despite the 11.2% net margin.
• Bears focus on that cash flow strain plus category and cost pressures, and the current data leaves room for those concerns to stay in play:
  • Even with earnings of US$756 million over the last 12 months, the warning that free cash flow does not comfortably cover the dividend means income focused investors are leaning on management’s ability to keep converting profits into cash.
  • The note that operating cash flow does not clearly cover debt, combined with only mid single digit forecast revenue growth of about 5.5% a year, supports the bearish view that balance sheet and payout commitments could limit financial flexibility if growth slows.

Skeptics watching the dividend and leverage coverage may keep treating Q3 as a proof point on whether earnings quality is strong enough to offset these balance sheet and cash flow concerns. 🐻 Clorox Bear Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Clorox on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With bulls and bears both finding support in the same set of numbers, the real edge comes from studying the details yourself and acting while the information is fresh. Start with a close look at the 4 key rewards and 2 important warning signs.

See What Else Is Out There

Clorox’s mixed picture on cash flow coverage for its 5.69% dividend and debt suggests its balance sheet and payouts may feel tighter than some investors prefer.

If you want income with fewer balance sheet headaches, it makes sense to size up companies screened for stronger coverage and resilience using the solid balance sheet and fundamentals stocks screener (44 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.